OrganiGram (OGI) Q2 2025 earnings summary

Executive summary

• Achieved record Q2 FY25 gross revenue of $102.8M (up 79% YoY) and net revenue of $65.6M (up 74% YoY), driven by Motif acquisition, organic growth, and strong operational results.

• Net income reached $42.5M, reversing a net loss of $27.1M YoY, mainly due to fair value gains on derivative liabilities and financial instruments.

• Maintained #1 market share in Canada across vapes, pre-rolls, milled flower, hash, and pure CBD gummies.

• Completed Motif and Collective Project acquisitions, expanding into beverages and strengthening U.S., Canadian, and international distribution.

• Closed final $41.5M tranche of $124.6M BAT investment, supporting R&D, M&A, and international expansion.

Financial highlights

• Gross sales/revenue up 79% YoY to $102.8M; net revenue up 74% YoY to $65.6M; international revenue up 177% YoY to $6.1M.

• Adjusted gross margin rose to $21.9M (33%), up from $11.6M (31%) YoY; standalone margin excluding Motif was 37%.

• Adjusted EBITDA reached $4.9M, up from negative $1M YoY; adjusted EBITDA margin 7.5%.

• Net income margin was 64.6% in Q2 FY25.

• Cash position at March 31 was $83.4M, with negligible debt and working capital of $182.9M.

Outlook and guidance

• Expecting continued revenue and margin growth in Q3 and Q4, with a long-term adjusted gross margin target of 40% in the second half of fiscal 2026.

• Motif integration expected to deliver $15M in annual cost synergies, exceeding original $10M estimate.

• Anticipate being cash flow positive for the full year, with strongest cash flow in Q3 and Q4.

• Focused on accelerating international revenue, expanding branded sales in the U.S. and Australia, and leveraging EU GMP certification.

• $59M remains in the Jupiter fund to support U.S. and international expansion.